ProMIS Neurosciences Inc. Common Shares (ON) (PMN)

About PMN

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic ol…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

10

Website

www.promisneurosciences.com/

Fundamentals

1-day range

$13.47$14.6

Market cap

$126.80M

P/E (trailing)

—

P/E (forward)

-2.96

EPS (trailing)

$-18.59

Dividend yield

—

Beta

-0.28

Avg. volume

83.1K

Forecasts

7 analyst ratings

ProMIS Neurosciences Inc. Common Shares (ON) Competitors

Chosen by industry and closest market cap.

• PMN

  ProMIS Neurosciences Inc. Common Shares (ON)

  $13.79

  ▼ 1.43%
  Market cap $126.80MP/E —
  $6.27$27.4
• IFRX

  InflaRx N.V. Common Stock

  $2.22

  ▼ 2.20%
  Market cap $126.51MP/E —
  $0.7984$2.95
• VTVT

  vTv Therapeutics Inc. Class A Common Stock

  $32.17

  ▼ 1.92%
  Market cap $127.58MP/E 55.59
  $15.79$44
• CNTB

  Connect Biopharma Holdings Limited Ordinary Shares

  $2.22

  ▼ 2.63%
  Market cap $124.04MP/E —
  $1.23$3.82
• ADCT

  ADC Therapeutics SA Common Shares

  $1.15

  ▲ 2.68%
  Market cap $133.55MP/E —
  $0.7796$4.98
• GNLX

  Genelux Corporation Common Stock

  $2.66

  ▼ 7.64%
  Market cap $133.62MP/E —
  $2.29$8.54
• SPRB

  Spruce Biosciences Inc. Common Stock

  $60.05

  ▼ 5.13%
  Market cap $118.73MP/E —
  $7$240

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
  benzinga · 8/14/2026
• Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
  Benzinga · 8/14/2026
• ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/13/2026
• ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
  Benzinga · 8/13/2026

• Johanne Kaplan · August 5, 2026 · Buy

  2.3K @ $13.3
• Eugene Williams · May 20, 2026 · Grant

  11.0K
• Eugene Williams · May 20, 2026 · Grant

  5.5K
• Neil K. Warma · May 20, 2026 · Grant

  160.0K
• Shafmaster Madge K. · May 20, 2026 · Grant

  11.0K
• Shafmaster Madge K. · May 20, 2026 · Grant

  5.5K
• Neil Cashman · May 20, 2026 · Grant

  50.0K
• Max A. Milbury · May 20, 2026 · Grant

  18.2K
• Josh Mandel-Brehm · May 20, 2026 · Grant

  11.0K
• Josh Mandel-Brehm · May 20, 2026 · Grant

  5.5K
• Johanne Kaplan · May 20, 2026 · Grant

  50.0K
• Alex Slanix Paul · May 20, 2026 · Grant

  11.0K
• Alex Slanix Paul · May 20, 2026 · Grant

  5.5K
• WYMAN WILLIAM W · May 20, 2026 · Grant

  11.0K
• WYMAN WILLIAM W · May 20, 2026 · Grant

  5.5K

Institutional Ownership

March 31, 2026

Total shares held

6.14M

Total value held

$78.02M

Institutional holders

25